Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isolated human pancreatic islets (Andrew Posselt-type) refers to an experimental allogeneic cell therapy investigated by Dr. Andrew Posselt at the University of California, San Francisco (UCSF). This therapy involves the isolation of insulin-producing islets from deceased donor pancreata and their subsequent transplantation into the gastric submucosa of patients with type 1 diabetes mellitus, particularly those with hypoglycemic unawareness. Unlike the conventional method of infusing islets into the portal vein, this approach utilizes endoscopic guidance to place the islets into the intestinal or gastric submucosal space, which is hypothesized to provide a more hospitable environment for islet survival and function. The primary goal is to restore endogenous insulin production and achieve better glycemic control, potentially leading to insulin independence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isolated human pancreatic islets.